JPWO2020077341A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020077341A5 JPWO2020077341A5 JP2021520159A JP2021520159A JPWO2020077341A5 JP WO2020077341 A5 JPWO2020077341 A5 JP WO2020077341A5 JP 2021520159 A JP2021520159 A JP 2021520159A JP 2021520159 A JP2021520159 A JP 2021520159A JP WO2020077341 A5 JPWO2020077341 A5 JP WO2020077341A5
- Authority
- JP
- Japan
- Prior art keywords
- bacterium
- bacteria
- family
- subject
- car
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000894006 Bacteria Species 0.000 claims description 319
- 238000000034 method Methods 0.000 claims description 140
- 238000011357 CAR T-cell therapy Methods 0.000 claims description 109
- 108010077805 Bacterial Proteins Proteins 0.000 claims description 55
- 206010028980 Neoplasm Diseases 0.000 claims description 28
- 230000015572 biosynthetic process Effects 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 28
- 241000095588 Ruminococcaceae Species 0.000 claims description 25
- 201000011510 cancer Diseases 0.000 claims description 24
- 241001607451 Oscillospiraceae Species 0.000 claims description 20
- 241001430149 Clostridiaceae Species 0.000 claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 241001112693 Lachnospiraceae Species 0.000 claims description 18
- 241000909284 Acidaminococcaceae Species 0.000 claims description 17
- 241000186660 Lactobacillus Species 0.000 claims description 17
- 241000692845 Rikenellaceae Species 0.000 claims description 16
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical group C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims description 14
- 241000606126 Bacteroidaceae Species 0.000 claims description 14
- 241001112692 Peptostreptococcaceae Species 0.000 claims description 14
- 239000003613 bile acid Substances 0.000 claims description 14
- 230000015556 catabolic process Effects 0.000 claims description 14
- 238000006731 degradation reaction Methods 0.000 claims description 14
- 230000001225 therapeutic effect Effects 0.000 claims description 14
- 235000019156 vitamin B Nutrition 0.000 claims description 14
- 239000011720 vitamin B Substances 0.000 claims description 14
- 241001013579 Anaerotruncus Species 0.000 claims description 12
- 241001134638 Lachnospira Species 0.000 claims description 12
- 241001464921 Phascolarctobacterium Species 0.000 claims description 12
- 241000202386 Pseudobutyrivibrio Species 0.000 claims description 12
- 241000040577 Romboutsia Species 0.000 claims description 12
- 229940039696 lactobacillus Drugs 0.000 claims description 12
- 241000904828 Clostridiaceae bacterium Species 0.000 claims description 9
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 8
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 8
- 108700003860 Bacterial Genes Proteins 0.000 claims description 8
- 102000007269 CA-125 Antigen Human genes 0.000 claims description 8
- 108010008629 CA-125 Antigen Proteins 0.000 claims description 8
- 229930003270 Vitamin B Natural products 0.000 claims description 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 7
- 241000801627 Alistipes indistinctus Species 0.000 claims description 6
- 241000428313 Anaerotruncus colihominis Species 0.000 claims description 6
- 241000949098 Coprococcus comes Species 0.000 claims description 6
- 241001134642 Lachnospira pectinoschiza Species 0.000 claims description 6
- 241000186840 Lactobacillus fermentum Species 0.000 claims description 6
- 241001438705 Lactobacillus rogosae Species 0.000 claims description 6
- 241001042460 Oscillibacter valericigenes Species 0.000 claims description 6
- 241001464924 Phascolarctobacterium faecium Species 0.000 claims description 6
- 241000202384 Pseudobutyrivibrio ruminis Species 0.000 claims description 6
- 241000605947 Roseburia Species 0.000 claims description 6
- 241001350461 [Clostridium] amygdalinum Species 0.000 claims description 6
- 241001656805 [Clostridium] methylpentosum Species 0.000 claims description 6
- 241001656794 [Clostridium] saccharolyticum Species 0.000 claims description 6
- 229940012969 lactobacillus fermentum Drugs 0.000 claims description 6
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 4
- 241000606219 Bacteroides uniformis Species 0.000 claims description 4
- 241000193171 Clostridium butyricum Species 0.000 claims description 4
- 101100218470 Clostridium scindens (strain JCM 10418 / VPI 12708) baiCD gene Proteins 0.000 claims description 4
- 101100218471 Clostridium scindens (strain JCM 10418 / VPI 12708) baiE gene Proteins 0.000 claims description 4
- 101100218472 Clostridium scindens (strain JCM 10418 / VPI 12708) baiF gene Proteins 0.000 claims description 4
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 241000711954 Rikenellaceae bacterium Species 0.000 claims description 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 4
- 230000002550 fecal effect Effects 0.000 claims description 4
- 210000003736 gastrointestinal content Anatomy 0.000 claims description 4
- 208000009326 ileitis Diseases 0.000 claims description 4
- 230000036210 malignancy Effects 0.000 claims description 4
- -1 panC Proteins 0.000 claims description 4
- 101150075473 pdxJ gene Proteins 0.000 claims description 4
- 101150100613 thiH gene Proteins 0.000 claims description 4
- 241000711932 Acidaminococcaceae bacterium Species 0.000 claims description 3
- 241000904817 Lachnospiraceae bacterium Species 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 44
- 239000003814 drug Substances 0.000 claims 9
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 241001009090 Peptococcaceae bacterium Species 0.000 claims 2
- 241000904830 Ruminococcaceae bacterium Species 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862745343P | 2018-10-13 | 2018-10-13 | |
| US62/745,343 | 2018-10-13 | ||
| US201862754347P | 2018-11-01 | 2018-11-01 | |
| US62/754,347 | 2018-11-01 | ||
| PCT/US2019/056137 WO2020077341A1 (fr) | 2018-10-13 | 2019-10-14 | Méthodes et compositions pour détecter et traiter les sujets susceptibles de répondre négativement à la thérapie par lymphocytes t à récepteur antigénique chimérique |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022512681A JP2022512681A (ja) | 2022-02-07 |
| JPWO2020077341A5 true JPWO2020077341A5 (fr) | 2022-10-21 |
| JP7486479B2 JP7486479B2 (ja) | 2024-05-17 |
Family
ID=70164424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021520159A Active JP7486479B2 (ja) | 2018-10-13 | 2019-10-14 | Ｃａｒ ｔ細胞療法応答不良のリスクがある対象を識別および処置するための方法および組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11860163B2 (fr) |
| EP (1) | EP3864414A4 (fr) |
| JP (1) | JP7486479B2 (fr) |
| CN (1) | CN113227792A (fr) |
| CA (1) | CA3116130A1 (fr) |
| WO (1) | WO2020077341A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021224185A1 (en) * | 2020-02-18 | 2022-09-15 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for identifying and treating subjects at risk of poor cancer survival |
| GB202007452D0 (en) | 2020-05-19 | 2020-07-01 | Microbiotica Ltd | Threrapeutic bacterial composition |
| EP4388120A1 (fr) * | 2021-08-17 | 2024-06-26 | Fondazione Per L'Istituto Oncologico Di Ricerca (IOR) | Les bactéries commensales favorisent la résistance endocrinienne dans le cancer de la prostate grâce à la biosynthèse des androgènes |
| WO2023081472A1 (fr) * | 2021-11-05 | 2023-05-11 | Memorial Sloan-Kettering Cancer Center | Méthodes et compositions pour prédire la survie du cancer et la toxicité des lymphocytes car-t |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2010645A4 (fr) * | 2006-04-20 | 2009-05-06 | Univ Singapore | Lactobacillus recombiné et utilisation de celui-ci |
| KR20170068504A (ko) * | 2014-10-08 | 2017-06-19 | 노파르티스 아게 | 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도 |
| JP2018515426A (ja) * | 2015-03-12 | 2018-06-14 | ザ ユニヴァーシティ オブ ブリティッシュ コロンビア | 細菌組成物およびその使用方法 |
| CN107530427A (zh) * | 2015-03-27 | 2018-01-02 | 南加利福尼亚大学 | 针对用于实体肿瘤的治疗的lhr的car t细胞疗法 |
| CA2997100A1 (fr) | 2015-09-04 | 2017-03-09 | Memorial Sloan-Kettering Cancer Center | Procedes et compositions pour detecter un risque de rechute de cancer |
| EP3368559A4 (fr) | 2015-10-30 | 2020-01-15 | Aleta Biotherapeutics Inc. | Compositions et méthodes pour le du traitement du cancer |
| RS57138B1 (sr) * | 2015-11-20 | 2018-07-31 | 4D Pharma Res Ltd | Kompozicije koje sadrže bakterijske sojeve |
| WO2017091694A1 (fr) * | 2015-11-24 | 2017-06-01 | Memorial Sloan-Kettering Cancer Center | Méthodes et compositions pour l'identification et le traitement de sujets à risque de développer une colite associée à une thérapie de blocage de points de contrôle |
| EP3518946A4 (fr) * | 2016-09-27 | 2020-09-09 | Board of Regents, The University of Texas System | Procédés permettant d'améliorer le traitement par blocage du point de contrôle immunitaire en modulant le microbiome |
| EP3559257A1 (fr) | 2016-12-22 | 2019-10-30 | Institut Gustave Roussy (IGR) | Composition de microbiote, à titre de marqueur de réactivité à des anticorps anti-pd1/pd-l1/pd-l2 et utilisation de modulateurs microbiens pour améliorer l'efficacité d'un traitement à base d'anticorps anti-pd1/pd-l1/pd-l2 |
| KR101833503B1 (ko) * | 2016-12-26 | 2018-03-05 | 주식회사 엠디헬스케어 | 만성폐쇄성폐질환자에서 세균 메타게놈 분석을 통한 폐암 진단방법 |
| CN108130297A (zh) * | 2018-01-19 | 2018-06-08 | 南昌大学 | 配合cart细胞治疗的复合益生菌菌剂、其制备方法及用途 |
-
2019
- 2019-10-14 WO PCT/US2019/056137 patent/WO2020077341A1/fr active Application Filing
- 2019-10-14 EP EP19871868.6A patent/EP3864414A4/fr active Pending
- 2019-10-14 JP JP2021520159A patent/JP7486479B2/ja active Active
- 2019-10-14 CN CN201980076411.XA patent/CN113227792A/zh active Pending
- 2019-10-14 CA CA3116130A patent/CA3116130A1/fr active Pending
-
2021
- 2021-04-13 US US17/229,184 patent/US11860163B2/en active Active
-
2023
- 2023-12-29 US US18/400,766 patent/US20240210395A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Neeman et al. | Prevalence of internalisation-associated gene, prtF1, among persisting group-A streptococcus strains isolated from asymptomatic carriers | |
| Cagnacci et al. | European emergence of ciprofloxacin-resistant Escherichia coli clonal groups O25: H4-ST 131 and O15: K52: H1 causing community-acquired uncomplicated cystitis | |
| Louie et al. | OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection | |
| Eren et al. | Clinical efficacy comparison of Saccharomyces boulardii and yogurt fluid in acute non-bloody diarrhea in children: a randomized, controlled, open label study | |
| Videlock et al. | Meta‐analysis: probiotics in antibiotic‐associated diarrhoea | |
| Madic et al. | Detection of Shiga toxin-producing Escherichia coli serotypes O26: H11, O103: H2, O111: H8, O145: H28, and O157: H7 in raw-milk cheeses by using multiplex real-time PCR | |
| Pagnini et al. | Mucosal adhesion and anti-inflammatory effects of Lactobacillus rhamnosus GG in the human colonic mucosa: A proof-of-concept study | |
| Gori et al. | Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis | |
| Rohde et al. | The use of probiotics in the prevention and treatment of antibiotic‐associated diarrhea with special interest in Clostridium difficile–associated diarrhea | |
| Delgado et al. | Antibiotic susceptibility of Lactobacillus and Bifidobacterium species from the human gastrointestinal tract | |
| Cantu-Jungles et al. | Dietary fiber hierarchical specificity: the missing link for predictable and strong shifts in gut bacterial communities | |
| Cristea et al. | Snapshot of phylogenetic groups, virulence, and resistance markers in Escherichia coli uropathogenic strains isolated from outpatients with urinary tract infections in Bucharest, Romania | |
| Crow et al. | Probiotics and fecal microbiota transplant for primary and secondary prevention of C lostridium difficile infection | |
| Ahmed et al. | Impact of probiotics on colonic microflora in patients with colitis: a prospective double blind randomised crossover study | |
| Doron et al. | Effect of Lactobacillus rhamnosus GG administration on vancomycin-resistant Enterococcus colonization in adults with comorbidities | |
| Hammad et al. | Towards a compatible probiotic–antibiotic combination therapy: assessment of antimicrobial resistance in the Japanese probiotics | |
| Mardaneh et al. | Isolation, identification and antimicrobial susceptibility pattern of Tatumella ptyseos strains isolated from powdered infant formula milk consumed in neonatal intensive care unit: first report from Iran | |
| McDowell et al. | Propionibacterium acnes in human health and disease | |
| Saarela et al. | Tetracycline susceptibility of the ingested Lactobacillus acidophilus LaCH-5 and Bifidobacterium animalis subsp. lactis Bb-12 strains during antibiotic/probiotic intervention | |
| Pérez-Jorge et al. | Prosthetic joint infection caused by Helcococcus kunzii | |
| Tiba-Casas et al. | Emergence of CMY-2-producing Salmonella Heidelberg associated with IncI1 plasmids isolated from poultry in Brazil | |
| El-Mahdy et al. | High level aminoglycoside resistant enterococci in hospital-acquired urinary tract infections in Mansoura, Egypt | |
| JPWO2020077341A5 (fr) | ||
| Massip et al. | The synergistic triad between microcin, colibactin, and salmochelin gene clusters in uropathogenic Escherichia coli | |
| Vray et al. | A multicenter, randomized controlled comparison of three renutrition strategies for the management of moderate acute malnutrition among children aged from 6 to 24 months (the MALINEA project) |